Cargando…

A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia

Several tyrosine kinase inhibitors (TKIs) have been developed as targeted therapies to inhibit the oncogenic activity of several tyrosine kinases in chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), gastrointestinal stromal tumor (GIST), and other diseases. TKIs have significantly impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Honglan, Gang, Dongxu, He, Xiaoyu, Jiang, Songfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772831/ https://www.ncbi.nlm.nih.gov/pubmed/36568202 http://dx.doi.org/10.3389/fonc.2022.1036437

Ejemplares similares

P370: EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULTS PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH T315I MUTATION AND RELAPSED/REFRACTORY DISEASE
por: Liu, Weiyang, et al.
Publicado: (2023)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
por: Imeri, Jusuf, et al.
Publicado: (2023)

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
por: Bocchia, Monica, et al.
Publicado: (2018)

Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI
por: Miao, Ya-Ru, et al.
Publicado: (2021)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
por: Lu, Rui, et al.
Publicado: (2017)

The TKI Era in Chronic Leukemias
por: De Novellis, Danilo, et al.
Publicado: (2021)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
por: Tang, Xin, et al.
Publicado: (2021)

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

A novel 10-gene ferroptosis-related prognostic signature in acute myeloid leukemia
por: Zhu, Kai, et al.
Publicado: (2022)

Transient TKI-resistant CD44+pBAD+ blasts undergo intrinsic homeostatic adaptation to promote the survival of acute myeloid leukemia in vitro
por: Xu, Yi, et al.
Publicado: (2023)

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
por: Giallongo, Cesarina, et al.
Publicado: (2015)

Genomics of Acute Myeloid Leukemia: The Next Generation
por: Riva, Laura, et al.
Publicado: (2012)

Therapeutic targeting of leukemia stem cells in acute myeloid leukemia
por: Barbosa, Karina, et al.
Publicado: (2023)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2023)

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
por: Izzo, Barbara, et al.
Publicado: (2019)

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience
por: Chitanava, Tamara, et al.
Publicado: (2023)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia
por: Tasian, Sarah K., et al.
Publicado: (2014)

Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2019)

Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
por: Zhang, Guoqing, et al.
Publicado: (2022)

Management of Chronic Myeloid Leukemia in Advanced Phase
por: Bonifacio, Massimiliano, et al.
Publicado: (2019)

Debating Frontline Therapy in Chronic Myeloid Leukemia
por: Bi, Xia, et al.
Publicado: (2021)

Editorial: Advances in the treatment of chronic myeloid leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2023)

Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia
por: Ding, Jianghua, et al.
Publicado: (2023)

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
por: Jiang, Bo, et al.
Publicado: (2023)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
por: Ward, Melea A., et al.
Publicado: (2015)

Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review
por: Li, Chunmou, et al.
Publicado: (2022)

A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021
por: Ding, Hanyi, et al.
Publicado: (2022)

Efficacy of Surgery in Patients with Stage I Primary Parotid Gland Lymphoma: A Population-Based Study
por: He, Xiaoyu, et al.
Publicado: (2022)

Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020)
por: Wang, Yue, et al.
Publicado: (2022)

Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia
por: Sun, Younguk, et al.
Publicado: (2018)

New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
por: Westerweel, Peter E., et al.
Publicado: (2019)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias
por: Bhingarkar, Aboli, et al.
Publicado: (2021)

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
por: Chen, Yilin, et al.
Publicado: (2023)

Atypical presentation of patients with chronic myeloid leukemia in chronic phase—Case report
por: Ramdohr, Florian, et al.
Publicado: (2022)

An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States
por: Kumar, Vivek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6ti3v9qr7frqg2jspq2ouc3j5t